Hemgenix (etranacogene dezaparvovec) is now available on the European market for the treatment of severe and moderately severe haemophilia B in adults without factor IX inhibitors (autoantibodies produced by the immune system that make drugs against factor IX less effective). The recommendation for the granting of marketing authorization in EU countries is from the